Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Etirinotecan pegol - Nektar Therapeutics

Drug Profile

Etirinotecan pegol - Nektar Therapeutics

Alternative Names: Irinotecan - Nektar Therapeutics; NKTR-102; ONZEALD; PEG-Irinotecan; Pegylated irinotecan - Nektar Therapeutics

Latest Information Update: 17 Sep 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nektar Therapeutics
  • Developer Clovis Oncology; Mayo Clinic; Nektar Therapeutics; Roswell Park Cancer Institute; Stanford University School of Medicine; University of Pennsylvania Cancer Center
  • Class Alkaloids; Antineoplastics; Camptothecins; Heterocyclic compounds with 4 or more rings; Indolizines; Piperidines; Polyethylene glycols; Quinolines
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Breast cancer
  • Phase II Colorectal cancer; Glioma; Non-small cell lung cancer; Ovarian cancer; Small cell lung cancer
  • No development reported Cervical cancer; Solid tumours

Most Recent Events

  • 01 Jul 2019 Nektar Therapeutics completes a phase II trial for Non-small cell lung cancer, Small cell lung cancer and Breast cancer (Metastatic disease, Second line therapy or greater, Late stage disease) in USA (NCT02312622)
  • 23 May 2019 Nektar Therapeutics and TrovaGene enter into a research collaboration agreement to investigate etirinotecan pegol and onvansertib combination in Colorectal cancer
  • 28 Dec 2018 No recent reports of development identified for preclinical development in Breast-cancer(Combination therapy) in USA (IV, Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top